$CTIC Recent Headlines Insider filings one way to track

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:14 AM

$CTIC Recent Headlines

Insider filings one way to track tricky micro-cap biotechs 11:14 a.m. Oct. 24, 2012 - blogs.marketwatch.com
Friday’s biggest gaining and declining stocks 3:27 p.m. Oct. 5, 2012 - Greg Morcroft
Cell Therapeutics down 21% in premarket 6:15 a.m. Oct. 5, 2012 - Steve Gelsi
Tuesday’s biggest gaining and declining stocks 3:53 p.m. Oct. 2, 2012 - MarketWatch
Cell Therapeutics up 21% in premarket 7:38 a.m. Oct. 2, 2012 - Steve Gelsi
CTIC gets orphan drug status for brain cancer drug 6:37 a.m. Oct. 2, 2012 - MarketWatch.com
Cell Therapeutics: progress with lymphoma Drug 5:59 a.m. Sept. 24, 2012 - MarketWatch.com
Tuesday’s top gaining and declining stocks 3:57 p.m. Sept. 11, 2012 - MarketWatch
Cell Therapeutics soars 24% on EU drug launch 9:12 a.m. Sept. 11, 2012 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 4:01 p.m. Sept. 4, 2012 - Greg Morcroft
Updates, advisories and surprises 4:01 p.m. July 31, 2012 - MarketWatch
Cell Therapeutics announces stock placement 10:45 a.m. July 31, 2012 - Val Brickates Kennedy
Friday’s biggest gaining and declining stocks 4:21 p.m. Feb. 17, 2012 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:49 p.m. Jan. 30, 2012 - Kate Gibson
Cell Therapeutics pulls application; shares slump 1:25 p.m. Jan. 30, 2012 - MarketWatch.com
Stocks to watch Monday: Blue Coat, Cooper 4:35 p.m. Dec. 9, 2011 - William Spain
Friday’s biggest gaining & declining stocks 4:35 p.m. Dec. 9, 2011 - Kate Gibson
Thursday’s biggest gaining & declining stocks 3:59 p.m. June 30, 2011 - Kate Gibson
Cell Therapeutics tumbles over offerings 8:09 a.m. June 30, 2011 - MarketWatch.com

Insider Trading Alert - CTIC, SAM And DGI Traded By Insiders 11:00 a.m. Nov. 7, 2014 - TheStreet.com
10-Q: CTI BIOPHARMA CORP 5:12 a.m. Oct. 31, 2014 - Edgar Online - (EDG = 10Q, 10K)
CTI BioPharma's (CTIC) CEO James Bianco on Q3 2014 Results - Earnings Call Transcript 2:10 a.m. Oct. 30, 2014 - Seeking Alpha
CTI BioPharma (CTIC) Q3 2014 Results - Earnings Call Webcast 3:25 p.m. Oct. 29, 2014 - Seeking Alpha
InsiderInsights.com Daily Round Up 9/24/14: Mercer International, OPKO Health, New Media, CTI BioPharma 7:17 a.m. Sept. 25, 2014 - Seeking Alpha
Merrimack Does Well to License Marginal Cancer Drug to Baxter 7:14 a.m. Sept. 24, 2014 - TheStreet.com
CTI BioPharma and Servier collaborate on cancer drug 7:19 a.m. Sept. 17, 2014 - Seeking Alpha
SEC Slaps Biotech Hedge Fund for Short-Selling Violations 12:04 p.m. Sept. 16, 2014 - TheStreet.com
CTI BioPharma set for gap up at the open 7:00 a.m. Sept. 9, 2014 - Seeking Alpha
Insider Trading Alert - MTDR, ABCO And CTIC Traded By Insiders 9:15 a.m. Aug. 18, 2014 - TheStreet.com
Insider Trading Alert - CMS, CTIC And WFT Traded By Insiders 9:15 a.m. Aug. 7, 2014 - TheStreet.com
CTI BioPharma's (CTIC) CEO Jim Bianco on Q2 2014 Results - Earnings Call Transcript 9:56 p.m. Aug. 4, 2014 - Seeking Alpha
10-Q: CTI BIOPHARMA CORP 4:07 p.m. Aug. 4, 2014 - Edgar Online - (EDG = 10Q, 10K)
CTI BioPharma (CTIC) Q2 2014 Results - Earnings Call Webcast 3:25 p.m. Aug. 4, 2014 - Seeking Alpha
Insider Trading Alert - AAWW, CTIC And HBI Traded By Insiders 9:12 a.m. July 10, 2014 - TheStreet.com
$4 Or Less: 2 Small Biotechs Moving On News 10:56 a.m. July 2, 2014 - Seeking Alpha
CTI completes clinical trial enrollment that sets up a milestone payment 6:23 a.m. July 1, 2014 - Seeking Alpha
Insider Trading Alert - FII, RP And CTIC Traded By Insiders 9:30 a.m. June 30, 2014 - TheStreet.com
Insider Trading Alert - FII, RP And CTIC Traded By Insiders 9:23 a.m. June 30, 2014 - TheStreet.com
Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders 9:16 a.m. June 9, 2014 - TheStreet.com

CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock 9:15 a.m. Nov. 7, 2014 - PR Newswire - PRF
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock 4:15 p.m. Nov. 6, 2014 - PR Newswire - PRF
CTI BioPharma Reports Third Quarter 2014 Financial Results 3:01 p.m. Oct. 29, 2014 - PR Newswire - PRF
CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy 1:30 a.m. Oct. 27, 2014 - PR Newswire - PRF
CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 12:30 a.m. Oct. 20, 2014 - PR Newswire - PRF
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma 8:15 a.m. Oct. 6, 2014 - PR Newswire - PRF
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI® 12:30 a.m. Sept. 17, 2014 - PR Newswire - PRF
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma 7:50 a.m. Aug. 25, 2014 - PR Newswire - PRF
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis 12:30 a.m. Aug. 7, 2014 - PR Newswire - PRF
CTI BioPharma Reports Second Quarter 2014 Financial Results 3:01 p.m. Aug. 4, 2014 - PR Newswire - PRF
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies 9:06 a.m. July 30, 2014 - ACCESSWIRE
CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 12:30 a.m. July 28, 2014 - PR Newswire - PRF
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands 12:30 a.m. July 21, 2014 - PR Newswire - PRF
Acquisitions, Study Results, Merger Agreements, and Completed Trial Recruitments - Analyst Notes on Cooper, Agenus, Transcept, CTI and ANI 5:00 a.m. July 4, 2014 - PR Newswire - PRF
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis 12:30 a.m. July 1, 2014 - PR Newswire - PRF
Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics 6:00 a.m. June 27, 2014 - PR Newswire - PRF
Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom 5:00 a.m. June 13, 2014 - PR Newswire - PRF
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS 12:30 a.m. June 12, 2014 - PR Newswire - PRF
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp. 12:30 a.m. May 30, 2014 - PR Newswire - PRF
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty 11:52 a.m. May 29, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

CapCut's AI Tools Reshape Video Content Creation

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

DigitalXForce Booms with 514% Growth and Major Backing

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...